曲唑酮与非典型抗精神病药用于老年出院后谵妄的安全性比较
该全国性队列研究采用目标试验模拟框架,纳入65岁以上无精神疾病、出院30天内新处方曲唑酮或非典型抗精神病药的谵妄患者,比较出院后安全结局。结果显示曲唑酮与较低的全因再住院、谵妄再住院、尿路感染和全因死亡风险相关,跌倒、肺炎和卒中风险无显著差异。
要点
- 与利培酮和奥氮平相比再住院风险降低,与喹硫平相比无差异。
核心结论
- 曲唑酮相比非典型抗精神病药与较低的再住院和全因死亡风险相关,可能是出院后谵妄相关症状管理的更安全替代。
研究设计与样本
- 基于美国Medicare(2013–2022年)和Optum Clinformatics数据库(2013–2025年)的全国性队列研究,采用目标试验模拟框架。
- 纳入65岁以上无精神疾病、出院30天内新处方曲唑酮或非典型抗精神病药(喹硫平、利培酮或奥氮平)且有谵妄诊断的住院患者。
- 使用倾向评分重叠加权调整162个协变量,采用Fine-Gray模型和Cox模型估计关联,两数据库结果用逆方差加权合并。
临床怎么用
- 对于出院后谵妄相关症状的老年患者,曲唑酮可作为非典型抗精神病药的潜在更安全替代选择。
- 选择具体药物时需注意,曲唑酮相对利培酮和奥氮平在再住院风险上更优,但相对喹硫平未见差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Trazodone has emerged as a potentially safer alternative to atypical antipsychotic medications for managing delirium-related symptoms in older adults after hospital admission. This study aimed to compare safety outcomes in older adults who were prescribed trazodone versus atypical antipsychotic medication after hospital discharge. METHODS: This population-based cohort study was done using US Medicare data from Jan 1, 2013, to Dec 31, 2022, and Optum de-identified Clinformatics Data Mart Database data from Jan 1, 2013, to Aug 31, 2025, with a target trial emulation framework. Patients aged at least 65 years without psychiatric disorders who were prescribed a new trazodone or atypical antipsychotic medication (quetiapine, risperidone, or olanzapine) prescription within 30 days of hospital discharge with a claims-based delirium diagnosis were included. We applied propensity score overlap weighting to adjust for 162 covariates. The primary outcome was all-cause rehospitalisation. Secondary outcomes included rehospitalisation for delirium, falls (including fall-related emergency department visits), pneumonia, urinary tract infections, stroke, and all-cause mortality. Treatment-outcome associations were estimated using the Fine-Gray model for non-fatal outcomes (presented as subdistribution hazard ratio [SDHR]) and the Cox model for all-cause mortality (presented as hazard ratio [HR]). Estimates from the two databases were pooled using inverse-variance weighting. FINDINGS: 11 678 trazodone and 29 590 atypical antipsychotic medication users were included. Compared with antipsychotic medications, trazodone was associated with lower risks of rehospitalisation (SDHR 0·95 [95% CI 0·91-0·98]), rehospitalisation for delirium (SDHR 0·80 [0·75-0·86]), urinary tract infection (SDHR 0·84 [0·72-0·99]), and all-cause mortality (HR 0·84 [0·79-0·90]); no significant difference was observed for falls (SDHR 0·93 [0·85-1·02]), pneumonia (SDHR 0·96 [0·79-1·16]), and stroke (SDHR 0·92 [0·77-1·11]). The reduced risk of rehospitalisation with trazodone was consistent when compared with risperidone (SDHR 0·89 [0·84-0·95]), and olanzapine (SDHR 0·88 [0·82-0·94]) but no difference was seen with quetiapine (SDHR 0·97 [0·93-1·01]). INTERPRETATION: These results revealed reduced risks of rehospitalisation and all-cause mortality associated with trazodone versus atypical antipsychotic medications. Trazodone is a potentially safer alternative to antipsychotic medications in the management of delirium-related symptoms after hospital discharge. FUNDING: National Institute on Aging.
引用
- Yang CT, Wilkins JM, Pritchard KT, et al. Safety outcomes of trazodone versus antipsychotics for delirium after hospital admission in adults aged 65 years and older: a nationwide cohort study using a target trial emulation framework. Lancet Healthy Longev. 2025. PMID: 41448219. doi:10.1016/j.lanhl.2025.100804
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。